Farzad Mostashari, MD, reflects on his tenure as the National Coordinator for Health Information Technology in an interview with Medscape Editor-in-Chief Eric J. Topol, MD.

What's in a word? Enough to 'set your hair on fire' if the word is cancer, says Dr. George Lundberg, who comments on the importance of not calling a lesion 'cancer' when it is not.

Cancer requires treatment, but what if low-risk lesions are no longer called cancer? Drs. Kathy Miller and Maurie Markman look at possible effects on screening, treatment, and public perception.

Dr. Bruce Cheson forecasts that the Sunshine Act, requiring physicians to disclose most payment and gifts from industry over $10, will bring showers of misinterpretation and could hinder research.

Henry Black discusses the challenge of managing blood pressure in the patient with intracerebral hemorrhage.

Two articles in the July 25 edition of the New England Journal of Medicine analyze the efficacy of a novel drug for pulmonary arterial hypertension (PAH).

Dr. John Marshall takes to his electronic chalkboard to tackle the problem of coordinating the separate agendas of cancer stakeholders, and finds a simple yet elegant solution.

Dr. David Kerr discusses time to tumor growth, a metric that outscored all other means of characterizing tumor response rate and correlated with overall survival in patients with colorectal cancer.

First eosinophilic esophagitis and now lymphocytic esophagitis -- Dr. David Johnson discusses how to recognize its characteristics and differentiate it from other esophageal diseases.

The results of this important trial fuel Dr. Samuel Goldhaber's excitement for new tools in the treatment of thrombosis.